Awakn Life Sciences Corp.

Recent News

  • Awakn Life Sciences Initiates Investigative Study of Novel Formulation of (S)-ketamine to Assess Dissociative Effect

    Toronto, Ontario--(Newsfile Corp. - January 24, 2023) - Awakn Life Sciences Corp. (NEO: AWKN) (OTCQB: AWKNF) (FSE: 954) ("Awakn"), a biotechnology company developing therapeutics to treat addiction with a near-term focus on Alcohol Use Disorder (AUD), announces today it has initiated an investigative study to establish the dissociative effect of a proprietary and patent pending formulation of (S)-ketamine and optimized route of administration to support commercialization in due course.Today's news builds on Awakn's announcement in August 2022 of a twelve-month...

    2023-01-24 7:30 AM EST
  • Awakn Life Sciences Reports Strong Q3 2022 Results with 27% Revenue Growth

    Toronto, Ontario--(Newsfile Corp. - December 15, 2022) - Awakn Life Sciences Corp.(NEO: AWKN) (OTCQB: AWKNF) (FSE: 954) ("Awakn"), a biotechnology company, researching, developing, and commercializing therapeutics to treat addiction with a near-term focus on Alcohol Use Disorder (AUD), announced today its financial results and business highlights for the three months ended October 31, 2022. All results are reported under International Financial Reporting Standards ("IFRS") and in Canadian dollars ("CAD"), unless otherwise specified.Anthony Tennyson, Chief Executive Officer of Awakn Life...

    2022-12-15 7:30 AM EST
  • Awakn Life Sciences' Phase III Trial to Be Delivered in the UK National Health Service (NHS)

    Toronto, Ontario--(Newsfile Corp. - December 13, 2022) - Awakn Life Sciences Corp. (NEO: AWKN) (OTCQB: AWKNF) (FSE: 954) ('Awakn'), a revenue-generating biotechnology company researching, developing, and commercializing therapeutics to treat addiction with a near-term focus on Alcohol Use Disorder (AUD), announces that its Phase III clinical trial exploring the use of ketamine-assisted therapy for the treatment of severe AUD will be delivered across seven NHS sites in the UK. The trial has also been approved for grant funding for 66%...

    2022-12-13 7:30 AM EST
  • Awakn Life Sciences Announces Signing of Lease for Second Clinic in Norway

    Toronto, Ontario--(Newsfile Corp. - December 1, 2022) - Awakn Life Sciences Corp. (NEO: AWKN) (OTCQB: AWKNF) (FSE: 954) ('Awakn'), a revenue-generating biotechnology company researching, developing, and commercializing therapeutics to treat addiction with a near-term focus on Alcohol Use Disorder (AUD), announces today the signing of a 5-year lease to open Awakn Clinics Trondheim. The new clinic is part of the second stage of Awakn's Nordic expansion plans, following on from last week's announcement of a move to a larger premises...

    2022-12-01 7:30 AM EST
  • Awakn Life Sciences Announces Location for Larger Oslo Clinic

    Toronto, Ontario--(Newsfile Corp. - November 23, 2022) -  Awakn Life Sciences Corp. (NEO: AWKN) (OTCQB: AWKNF) (FSE: 954) ('Awakn'), a revenue-generating biotechnology company researching, developing, and commercializing therapeutics to treat addiction with a near-term focus on Alcohol Use Disorder (AUD), announces today the signing of a 5-year lease to open a larger Awakn Clinics Oslo. The move to the new Oslo premises is the first stage of Awakn's Nordic expansion plans. Awakn Clinics Oslo's new location will be a 6-treatment...

    2022-11-23 7:30 AM EST
  • Awakn Life Sciences Announces Closing of Private Placement

    Toronto, Ontario--(Newsfile Corp. - November 17, 2022) - Awakn Life Sciences Corp. (NEO: AWKN) (OTCQB: AWKNF) (FSE: 954) ("Awakn"), a revenue-generating biotechnology company researching, developing, and commercializing therapeutics to treat addiction with a near-term focus on Alcohol Use Disorder (AUD), is pleased to announce that, further to its press release dated September 15, 2022, it has closed a second and final tranche (the "Second Tranche") of its previously announced non-brokered private placement (the "Offering") through the issuance of an additional...

    2022-11-17 7:30 AM EST
  • Awakn Life Sciences Signs Its Third Licensing Partnership Agreement in North America, and First in New York

    Toronto, Ontario--(Newsfile Corp. - November 9, 2022) - Awakn Life Sciences Corp. (NEO: AWKN) (OTCQB: AWKNF) (FSE: 954) ('Awakn'), a revenue-generating biotechnology company researching, developing, and commercializing therapeutics to treat addiction with a near-term focus on Alcohol Use Disorder (AUD), announces it has signed its third Licensing Partnership agreement in North America. The agreement is with Nushama a leading network of ketamine-assisted therapy centers that exist to humanize medicine, together they will bring Awakn's Ketamine-assisted therapy treatment for AUD to...

    2022-11-09 7:30 AM EST
  • Awakn Life Sciences Secures Funding to Expand Nordic Commercial Operations

    Toronto, Ontario--(Newsfile Corp. - October 25, 2022) - Awakn Life Sciences Corp. (NEO: AWKN) (OTCQB: AWKNF) (FSE: 954) ("Awakn"), a revenue-generating biotechnology company researching, developing, and commercializing therapeutics to treat addiction with a near-term focus on Alcohol Use Disorder (AUD), today announces that its wholly-owned subsidiary Awakn Oslo AS ("Awakn Oslo") has entered into a debt financing agreement (the "Loan Agreement") with TD Veen AS (the "Lender"), a family-owned, Norwegian investment company and current shareholder of Awakn.Given the strong...

    2022-10-25 7:30 AM EDT